Jaypirca (pirtobrutinib) — Highmark
Chronic Lymphocytic Leukemia (CLL)
Initial criteria
- age ≥ 18 years
- diagnosis of CLL or SLL
- received at least two prior lines of therapy, including at least one from all of the following classes: BTK inhibitor and BCL-2 inhibitor